Hyperkalemia News and Research

RSS
Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Aldosterone/renin ratio reliable diagnostic tool in infant primary hypoaldosteronism

Aldosterone/renin ratio reliable diagnostic tool in infant primary hypoaldosteronism

New oral drug shows promise in patients with chronic kidney disease

New oral drug shows promise in patients with chronic kidney disease

Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Four-step process delivers specific, reliable clinical rules

Four-step process delivers specific, reliable clinical rules

Dual renin angiotensin system blockade: too many cons

Dual renin angiotensin system blockade: too many cons

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Eplerenone shown to reduce cumulative heart failure hospitalisations

Eplerenone shown to reduce cumulative heart failure hospitalisations